美诺华子公司阿托伐他汀钙原料药通过CDE技术审评

Core Viewpoint - The company Minohua (603538.SH) has received approval from the National Medical Products Administration for the marketing application of atorvastatin calcium raw material, which will enhance its product line and business scope [1] Group 1: Regulatory Approval - Minohua's subsidiary, Xuancheng Minohua Pharmaceutical Co., Ltd., has obtained the approval notice for atorvastatin calcium raw material from the National Medical Products Administration [1] - The atorvastatin calcium raw material has passed the CDE technical review, confirming its compliance with national drug review technical standards [1] Group 2: Business Expansion - The approval will enrich the product line of the subsidiary, aiding in the expansion of the company's business areas [1] - It is expected to further extend the company's integrated production range of raw materials and formulations, enhancing its integrated production advantages [1]